Enstilar (calcipotriene-betamethasone foam) is filed as Topical Antipsoriatic. The sections below restate public label fields stored for this profile.
Enstilar ® (calcipotriene and betamethasone dipropionate) Foam is indicated for the topical treatment of plaque psoriasis in patients 12 years and older.
Enstilar Foam combines the pharmacological effects of calcipotriene hydrate as a synthetic vitamin D3 analog and betamethasone dipropionate as a synthetic corticosteroid. However, while their pharmacologic and clinical effects are known, the exact mechanisms of their actions in the treatment of plaque psoriasis are unknown.
4 CONTRAINDICATIONS None. None. ( 4 )
Shake can prior to using Enstilar Foam. Apply Enstilar Foam to affected areas once daily for up to 4 weeks. The maximum dose should not exceed 60 grams every 4 days. Rub in Enstilar Foam gently. Wash hands after applying the product. Discontinue Enstilar Foam when control is achieved. Enstilar Foam should not be used: with occlusive dressings unless directed by a healthcare provider. on the face, groin, or axillae, or if skin atrophy is present at the treatment site. Enstilar Foam is not for oral, ophthalmic, or intravaginal use.
According to its FDA label, Enstilar (calcipotriene-betamethasone foam) is approved for: Enstilar ® (calcipotriene and betamethasone dipropionate) Foam is indicated for the topical treatment of plaque psoriasis in patients 12 years and older. For medical advice, please talk to your prescriber or pharmacist.
Enstilar (calcipotriene-betamethasone foam) belongs to the Topical Antipsoriatic class of medications.
The FDA label lists Enstilar (calcipotriene-betamethasone foam) as: Flammability: The propellants in Enstilar Foam are flammable. Instruct the patient to avoid fire, flame, and smoking during and immediately following application. ( 5.1 ) Hypercalcemia and Hypercalciuria: Hypercalcemia and hypercalciuria have been observed with use of Enstilar Foam. If hypercalcemia or hypercalciuria develop, discontinue treatment until parameters of calcium metabolism have normalized. ( 5.2 ) Effects on Endocrine System: Topical corticosteroids can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for glucocorticosteroid insufficiency during and after withdrawal of treatment. Risk factors include the use of high-potency topical corticosteroids, use over a large surface area or on areas under occlusion, prolonged use, altered skin barrier, liver failure, and use in pediatric patients. Modify use should HPA axis suppression develop. ( 5.3 , 8.4 ) Ophthalmic Adverse Reactions: Topical corticosteroid products may increase the risk of cataracts and glaucoma. If visual symptoms occur, consider referral to an ophthalmologist. ( 5.5 ); topical route. Available strengths and packaging vary by manufacturer.
Our ingest of the FDA label for Enstilar (calcipotriene-betamethasone foam) does not include a Boxed Warning at this time. See the full label on DailyMed for the current, authoritative version.
Public CMS NADAC pricing for Enstilar (calcipotriene-betamethasone foam) is in the range Retail prices vary widely by pharmacy, insurance, and location. Check with your pharmacy or use tools like GoodRx for current pricing.. Retail price varies by pharmacy, insurance, and manufacturer coupons.
The FDA Enforcement Report does not show an active/ongoing recall for Enstilar (calcipotriene-betamethasone foam) in our latest ingest. Recall data can change daily — verify at FDA.gov.
The FDA record lists the approval date for Enstilar (calcipotriene-betamethasone foam) as 2015-10-16.
The FDA label lists LEO Pharma Inc. as a labeler/manufacturer of Enstilar (calcipotriene-betamethasone foam). Multiple firms may market generics of the same molecule.
The FDA label states: "Enstilar (calcipotriene and betamethasone dipropionate) Foam, 0.005%/0.064% is a white to off-white opalescent liquid in a pressurized aluminum spray can with a continuous valve and actuator. At administration, the produ…" Follow the packaging insert for the authoritative guidance.
Loading full data from Know Your Drugs Institute…